Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Xenleta“
Suchtreffer
Begriffe & Kennungen
Xenleta · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenXenleta · 4.3 · Known QT prolongation.
Eintrag öffnenXenleta · 4.3 · Known QT prolongation.
Eintrag öffnenXenleta · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenXenleta · 4.4 Special warnings and precautions for use · 2
Eintrag öffnenXenleta · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenXenleta · 4.5 Interaction with other medicinal products and other forms of interaction · 2
Eintrag öffnenXenleta · 4.5 · (Inhibition of BCRP, OATP1) SEDATIVE AGENTS Midazolam — Midazolam 1.03 1.17 No dose adjustment 2 mg oral singl
Eintrag öffnenXenleta · 4.5 · (Inhibition of CYP3A, BCRP, OATP1) SEDATIVE AGENTS Midazolam — Midazolam 2.03 3.07 Caution is recommened. 2 mg
Eintrag öffnenXenleta · 4.5 · (Inhibition of CYP3A4) HIV-ANTIVIRAL AGENTS Efavirenz * Not studied Co-administration of 600 mg once daily Exp
Eintrag öffnenXenleta · 4.5 · (Inhibition of CYP3A4) HIV-ANTIVIRAL AGENTS Efavirenz * Not studied Co-administration of 600 mg once daily Exp
Eintrag öffnenXenleta · 4.5 · (Inhibition of P-gp) ANTIDEPRESSANTS Fluvoxamine* Not studied No dose adjustment 100 mg twice daily Expected ↔
Eintrag öffnenXenleta · 4.5 · (Strong inhibiton of CYP3A4) Fluconazole* Not studied Co-administration of 400 mg day 1 + 200 Expected ↔ medic
Eintrag öffnenXenleta · 4.5 · 17 Effects of other products on lefamulin
Eintrag öffnenXenleta · 4.5 · 18 Repaglinide* Not studied Co-administration with 0.25 mg single dose Expected lefamulin may lead to ↑Repagli
Eintrag öffnenXenleta · 4.5 · 19 St. John’s Wort Not studied Co-administration of Expected: ↓ Lefamulin strong CYP3A inducers (Strong induct
Eintrag öffnenXenleta · 4.5 · 4 Use with strong CYP3A/P-gp inhibitors Medicinal products that are strong CYP3A and P-gp inhibitors (e.g. cla
Eintrag öffnenXenleta · 4.5 · 5 Medicinal product by therapeutic Effect on areas/possible medicinal Cmax AUC Clinical comments mechanism of
Eintrag öffnenXenleta · 4.5 · Co-administration of lefamulin with medicinal products metabolised by CYP2C8 (e.g. repaglinide) may result in
Eintrag öffnenXenleta · 4.5 · Co-administration of lefamulin with other medicinal products known to prolong the QT interval is contraindicat
Eintrag öffnen